Latent infection with Epstein-Barr virus (EBV) is associated with several human cancers, including nasopharyngeal cancer. During latent EBV infections, the glycine-alanine repeat (GAr) domain of the EBV nuclear antigen-1 (EBNA1) inhibits translation of EBNA1 mRNA, thereby suppressing the production of antigenic peptides that the human immune system recognises as foreign. Here, Blondel et al. establish a yeast-based assay that recapitulates GAr-mediated suppression of EBNA1 mRNA translation and use it to identify doxorubicin and its active analogues as compounds that specifically interfere with GAr-mediated suppression of translation. Importantly, in mammalian cells, doxorubicin and its analogues stimulate EBNA1 expression in a GAr-dependent manner and overcome the GAr-dependent restriction of antigen presentation. Together, these results validate the yeast-based assay as an effective cell-based screening approach for compounds that interfere with EBV immune evasion and that might, therefore, provide treatments for EBV-related diseases, including cancer. Page 435
- © 2014. Published by The Company of Biologists Ltd
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Article navigation
Related articles
Cited by...
More in this TOC section
Similar articles
Other journals from The Company of Biologists
DMM and COVID-19
We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.
Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.
Alessandro Bailetti is awarded the DMM Outstanding Paper Prize 2019
The annual prize is awarded to the first author of the paper that is judged by the journal’s editors to be the most outstanding contribution to the journal that year. Alessandro Bailetti's winning paper presents results that indicate a possible connection between E(Pc) and the Tip60 complex, and leukemia. Find out more about Alessandro and read the winning paper.
Find DMM online
We may not be meeting you in person this year, but we’re always here to chat about DMM and The Company of Biologists. Join the conversation over on Twitter, email us or catch Scientific Editor Julija Hmeljak at these upcoming virtual meetings:
MRC Human Genetics Unit (Virtual) Symposium: Aberrant Cell State Transitions in Human Disease
23-24 September
Genomic Imprinting – from Biology to Disease
28 September – 1 October
ZDMS Virtual webinar series
Throughout September – December
Interview - Pratibha Singh
First author Pratibha Singh discusses her intestinal injury model in mouse neonatal pups, the most significant challenge impacting her field of research and shares her thoughts on how to better support early-career researchers.
Call for papers - The RAS Pathway: Diseases, Therapeutics and Beyond
DMM invites you to submit original research for a special issue focused on targeting the RAS pathway. The submission deadline is 1 March 2021. Find out more and showcase your breakthrough research in this special collection.
It’s a time of turmoil for young scientists
“My students are my priority – they are on the brink of their careers.”
Dr Jodie Rummer (ARC Centre of Excellence for Coral Reef Studies at James Cook University) talks about the importance of her role as a supervisor in supporting graduate students and post docs financially, intellectually and emotionally during this period of uncertainty.